Development of respirable nanomicelle carriers for delivery of amphotericin B by jet nebulization

Journal of Pharmaceutical Sciences

Volumn 100, Issue 1, 2011, Pages 252-259

  Gilani, Kambiz ^a   Moazeni, Esmaeil ^a   Ramezanli, Tannaz ^a   Amini, Mohsen ^a   Fazeli, Mohammad Reza ^a   Jamalifar, Hossein ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Aerosols; Antiinfectives; Micelle; Nanoparticles; Pulmonary drug delivery

Indexed keywords

AMPHOTERICIN B; CHITOSAN; DRUG CARRIER; NANOMATERIAL; NANOMICELLE; STEARIC ACID; UNCLASSIFIED DRUG;

AEROSOL; ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NANOENCAPSULATION; NEBULIZATION; NONHUMAN; PHYSICAL CHEMISTRY;

EID: 78650061557     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22274     Document Type: Article

References (28)

1. Drew R. 2006. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections. Int J Antimicrob Agents 27S: S36-S44.
2. Chen K-Y, Ko S-C, Hsuesh P-R, Luh K-T, Yang P-C. 2001. Pulmonary fungal infections: Emphasis on microbiological spectra, patient outcome and prognostic factors. Chest 120: 177-184.
3. Behre GF, Schwartz S, Lenz K, Ludwig WD, Wandt H, Schilling E, Heinemann V, Link H. 1995. Aerosol amphotericin B inhalation for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann Hematol 71: 287-291.
4. Atkins PJ, Crowder TM. 2004. The design and development of inhalation drug delivery systems. In: Hickey AJ, editor. Pharmaceutical inhalation aerosol technology. 2nd edition. New York: Marcel Dekker, Inc. pp 279-309.
5. Williams DM. 2004. The application of aerosolized antimicrobial therapies in lung infections. In: Hickey AJ, editor. Pharmaceutical inhalation aerosol technology. 2nd edition. New York: Marcel Dekker, Inc. pp 473-488.
6. Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WCJ, Ruijgrok EJ. 2008. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: A randomized, placebo-controlled trial. Clin Infect Dis 46: 1401-1408.
7. Gallis HA, Drew RH, Pickard WW. 1990. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12: 308-329.
8. Torrado JJ, Espada R, Ballesteros MP, Torrado-Santiago S. 2008. Amphotericin B formulations and drug targeting. J Pharm Sci 97: 2405-2425.
9. Yu BG, Okano T, Kataoka K, Sardari S, Kwon GS. 1998. In vitro dissociation of antifungal efficacy and toxicity of amphotericin B-loaded poly(ethylene oxide)-block-poly(β-benzyl-L-aspartate) micelles. J Control Release 56: 285-291.
10. Croy SR, Kwon GS. 2006. Polymeric micelles for drug delivery. Curr Pharm Des 12: 4669-4684.
11. Jones M-C, Leroux J-C. 1999. Polymeric micelles-A new generation of colloidal drug carriers. Eur J Pharm Biopharm 48: 101-111.
12. Adams ML, Kwon GS. 2002. Relative aggregation and the hemolytic activity of amphotericin B encapsulated by poly(ethylene oxide)-block-poly(N-hexyl-L-aspartamide)-acyl conjugate micelles: Effects of acyl chain length. J Control Release 87: 23-32.
13. Vakil R, Kuldipkumar A, Andes D, Tan Y, Kwon GS. 2006. Polymeric micelles for drug delivery of polyene antibiotics. In: Svenson S, editor. Polymeric drug delivery. 1st edition. Washington, DC: American Chemical Society. pp 14-26.
14. Ye Y-Q, Chen F-Y, Wu Q-A, Hu F-Q, Du Y-Z, Yuan H, Yu H-Y. 2009. Enhanced cytotoxicity of core modified chitosan based polymeric micelles for doxorubicin delivery. J Pharm Sci 98: 704-712.
15. Hu F-Q, Ren G-F, Yuan H, Du Y-Z, Zeng S. 2006. Shell cross-linked stearic acid grafted chitosan oligosacharide self-aggregated micelles for controlled release of paclitaxel. Colloids Surf 50: 97-103.
16. Wu Y, Li M, Gao H. 2008. Polymeric micelle composed of PLA and chitosan as a drug carrier. Polymers 16: 11-18.
17. Kim C-J. 2004. Polymer science. Advanced pharmaceutics: Physiochemical principals. 1st edition. Boca Raton, FL: CRC Press.
18. Peniston QP, Johnson EL. 1975. Process for depolymerization of chitosan. United States Patent.
19. Lee KY, Kwon IC, Kim Y-H, Jo WH, Jeong SY. 1998. Preparation of chitosan self-aggregates as a gene delivery system. J Control Release 51: 213-220.
20. Lavasanifar A, Samuel J, Sattari S, Kwon GS. 2002. Block copolymer micelles for the encapsulation and delivery of amphotericin B. Pharm Res 19: 418-422.
21. Mao S, Shuai X, Unger F, Simon M, Bi D, Kissel T. 2004. The depolymerization of chitosan: Effects on physicochemical and biological properties. Int J Pharm 281: 45-54.
22. Zhang Y, Huo M, Zhou J, Yu D, Wu Y. 2009. Potential of amphiphilically modified low molecular weight chitosan as a novel carrier for hydrophobic anticancer drug: Synthesis, characterization, micellization and cytotoxicity evaluation. Carbohydr Polym 77: 231-238.
23. Barwicz J, Christian S, Gruda I. 1992. Effects of the aggregation state of amphotericin b on its toxicity to mice. Antimicrob Agents Chemother 36: 2310-2315.
24. Tiaboonchai W, Limpeanchob N. 2007. Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles. Int J Pharm 329: 142-149.
25. Tam JM, McConville JT, Williams RO III, Johnston KP. 2008. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. J Pharm Sci 97: 4915-4933.
26. Hickey AJ, Lu D, Ashley ED, Stout J. 2006. Inhaled azithromycin therapy. J Aerosol Med 19: 54-60.
27. Elhissi AMA, Faizi M, Naji WF, Gill HS, Taylor KMG. 2007. Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures. Int J Pharm 334: 62-70.
28. Zaru M, Mourtas S, Klepetsanis P, Fadda AM, Antimisiaris SG. 2007. Liposomes for drug delivery to the lungs by nebulization. Eur J Pharm Biopharm 67: 655-666.